Next |
home / stock / eols / eols message board
Subject | By | Source | When |
---|---|---|---|
Big buy in $EOLS OTM $10 May calls | boraborak38 | investorshub | 04/28/2023 5:12:15 PM |
$EOLS 4Q22 CC transcript: | DewDiligence | investorshub | 03/09/2023 9:46:54 PM |
Yeah.that was the only surprise. They have been | boraborak38 | investorshub | 03/09/2023 12:54:57 AM |
The only surprise is the refreshed $250M shelf | DewDiligence | investorshub | 03/09/2023 12:14:12 AM |
No surprises here. | boraborak38 | investorshub | 03/08/2023 10:32:20 PM |
$EOLS reports 4Q22 results: | DewDiligence | investorshub | 03/08/2023 9:16:29 PM |
Cant wait for Aeon to be done. If | boraborak38 | investorshub | 02/22/2023 11:19:26 PM |
Aeon sold 44% of its remaining $EOLS shares | DewDiligence | investorshub | 02/22/2023 9:12:46 PM |
I really think you are reaching on this | boraborak38 | investorshub | 02/19/2023 1:13:24 AM |
I dont see that as clearly. But your | boraborak38 | investorshub | 02/17/2023 3:39:59 AM |
What the CEO clearly means by the "not | DewDiligence | investorshub | 02/17/2023 1:10:00 AM |
Comments pertain to what? That they arent including | boraborak38 | investorshub | 02/17/2023 1:01:28 AM |
Maybe. Aeon Biopharma ($EOLS' former parent company) does | DewDiligence | investorshub | 02/16/2023 11:43:24 PM |
There isnt going to be a real accurate | DewDiligence | investorshub | 02/16/2023 11:41:54 PM |
Like it or not, Evolus is going to | boraborak38 | investorshub | 02/16/2023 10:32:10 PM |
LOL? You do understand that they use the | boraborak38 | investorshub | 02/16/2023 10:29:30 PM |
$EOLS 2028 forecast of $500M in sales includes | DewDiligence | investorshub | 02/14/2023 6:47:50 PM |
Court ruling in Korea against Daewoong may end $EOLS sales of Jeuveau(a/k/a BTX): | DewDiligence | investorshub | 02/10/2023 9:40:56 AM |
$EOLS' double-dose dataset cannot be trusted... | DewDiligence | investorshub | 01/30/2023 11:50:48 PM |
$EOLS CC slides for double-dose Jeuveausee comments below: | DewDiligence | investorshub | 01/30/2023 11:48:53 PM |
News, Short Squeeze, Breakout and More Instantly...
The article published in Aesthetic Surgery Journal supports safety and duration of effect for temporary improvement in the appearance of moderate to severe glabellar lines presented at the 2023 ASDS Annual Meeting Data showed duration effect of 26 weeks, or 6 months, based on a ≥ 1...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following investor conference in April: Event: The 23 rd Annual Needham Virtual Healthcare Conference Date...
2024-03-12 04:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...